Royalty Pharma Plc Stock Price, News & Analysis

Royalty Pharma (RPRX) has agreed to acquire the residual royalty interest in Vertex Pharmaceuticals' cystic fibrosis treatments from the Cystic Fibrosis Foundation for $575 million, with a potential additional $75 million in milestone payments. This transaction allows Royalty Pharma to retain all royalties above the previous $5.8 billion revenue threshold. The Vertex CF franchise generated over $4.0 billion in net revenues in 2019. This acquisition is expected to bolster Royalty Pharma's Adjusted Cash Receipts and Cash Flow growth, reflecting their commitment to funding biopharmaceutical innovation.

Royalty Pharma announced the closing of a secondary offering of 17,343,037 Class A ordinary shares at $42.00 per share. Proceeds from the sale will not benefit the company, as the shares were sold by existing shareholders. The SEC declared the registration statement effective on October 15, 2020. The offering was managed by major financial institutions including J.P. Morgan and Morgan Stanley. Royalty Pharma is a prominent buyer of biopharmaceutical royalties and funds innovation in the sector, holding royalties on over 45 commercial products.

Royalty Pharma (Nasdaq: RPRX) plans to report its third quarter 2020 financial results on November 11, 2020, prior to the U.S. market opening. A conference call will be held at 8:00 a.m. ET that day, accessible via phone at (833) 519-1253 or (914) 800-3826 for international callers, using passcode 8067315. The live webcast will be available on the company’s Investors page. Royalty Pharma is recognized as the largest buyer of biopharmaceutical royalties and a key innovator in the biopharmaceutical sector.

Royalty Pharma plc (Nasdaq: RPRX) has priced a secondary offering of 17,343,037 Class A ordinary shares at $42.00 per share, with selling shareholders and an option for underwriters to purchase an additional 2,601,455 shares. The company will not receive any proceeds from this sale. The offering is expected to close on October 20, 2020. Major banks such as J.P. Morgan and Morgan Stanley are leading the underwriting process. This offering comes as part of Royalty Pharma's strategy, positioning the company within the biopharmaceutical sector, focusing on royalties and innovation funding.

The board of directors of Royalty Pharma has approved a dividend of $0.15 per class A share for the fourth quarter of 2020. This dividend is set to be paid on December 15, 2020, to shareholders recorded by the close of business on November 20, 2020. Royalty Pharma is known for being the largest buyer of biopharmaceutical royalties, holding a portfolio that includes royalties on over 45 commercial products from major therapeutics companies.

Royalty Pharma plc (Nasdaq: RPRX) plans to offer 17,343,037 Class A ordinary shares in a public offering, with an option for underwriters to purchase an additional 2,601,455 shares. Proceeds from this offering will not benefit the company as they are for selling shareholders. Major underwriters include J.P. Morgan, Morgan Stanley, and Goldman Sachs. A registration statement has been filed with the SEC but is not yet effective, meaning shares cannot be sold until it is.

Royalty Pharma has completed a $6 billion offering of senior unsecured notes comprised of several tranches, maturing from 2023 to 2050. The proceeds will be used to repay existing term loans and cover related expenses. The offering was privately placed, exempt from registration under the Securities Act. Interest payments will occur semi-annually starting March 2021, reducing 2020 cash interest expense compared to prior loans. Royalty Pharma remains a key player in biopharmaceutical royalties, holding interests in over 45 commercial products, including drugs from major companies like AbbVie and Gilead.

Royalty Pharma has priced a $6 billion offering of senior unsecured notes, which includes various tranches maturing between 2023 and 2050. The offering aims to refinance existing loans and enhance financial flexibility, with a weighted average coupon of 2.125% and a maturity extension to 12.5 years. The notes are set for completion around September 2, 2020, and will be secured by Royalty Pharma Holdings Ltd. This deal will reduce the company's interest expense for 2020, transitioning from quarterly to semi-annual payments.

Royalty Pharma (RPRX) reported robust second-quarter 2020 results, showing a 33% rise in GAAP net cash from operating activities to $489 million. Adjusted Cash Receipts surged 24% to $462 million. The company anticipates 2020 Adjusted Cash Receipts between $1.720 billion and $1.760 billion, driven by a series of acquisitions totaling $1.7 billion. Key FDA approvals for drugs like Evrysdi and Trodelvy have enhanced their portfolio. Their IPO raised $1.9 billion, fueling future growth.